Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amedisys

UnitedHealth's $33B Deal With Hospice Provider Blocked By DOJ

The United States Department of Justice is suing to block UnitedHealth Group's $3.3 billion acquisition of Amedisys, arguing that it would harm competition.

International Business Times

Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys

Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys

The Justice Department is suing to block UnitedHealth Group’s $3.3 billion purchase of Amedisys

The Independent UK

Stock Market Today: Stocks end lower amid Trump's China moves

Stock Market Today: Stocks end lower amid Trump's China moves

The post-election rally will face the return of the bond market Tuesday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

UnitedHealth buying home health care provider in $3.3B deal

UnitedHealth Group has struck a deal to acquire home health care provider Amedisys Inc. for $3.3 billion in an all-cash deal.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022

Stephens & Co. Maintains Equal-Weight Rating for Amedisys: Here's What You Need To Know

Stephens & Co. has decided to maintain its Equal-Weight rating of Amedisys (NASDAQ:AMED) and lower its price target from $155.00 to $125.00. Shares of Amedisys are trading down 12.59% over the last 24 hours, at $106.09 per share.

inkl

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Amedisys

Analyst Ratings for Amedisys

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Analyst Ratings for Amedisys

Analyst Ratings for Amedisys

Over the past 3 months, 5 analysts have published their opinion on Amedisys (NASDAQ:AMED) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

7 Analysts Have This to Say About Amedisys

7 Analysts Have This to Say About Amedisys

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Where Amedisys Stands With Analysts

Where Amedisys Stands With Analysts

Analysts have provided the following ratings for Amedisys (NASDAQ:AMED) within the last quarter:

Amedisys: Q4 Earnings Insights

Amedisys: Q4 Earnings Insights

Amedisys (NASDAQ:AMED) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amedisys reported in-line EPS of $1.18 versus an estimate of $1.18.

1

People

Robert Lighthizer

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

British Airways

the Justice Department

UnitedHealth Group

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

236,570 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play